Câncer cervical

Referências

Principais artigos

Marth C, Landoni F, Mahner S, et al. Cervical cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017 Jul 1;28(suppl 4):iv72-83.Texto completo  Resumo

Fontham ETH, Wolf AMD, Church TR, et al. Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society CA Cancer J Clin. 2020 Sep;70(5):321-46.Texto completo  Resumo

Bhatla N, Aoki D, Sharma DN, et al. Cancer of the cervix uteri: 2021 update. Int J Gynaecol Obstet. 2021 Oct;155 Suppl 1(suppl 1):28-44.Texto completo  Resumo

National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: cervical cancer [internet publication].Texto completo

Artigos de referência

1. WHO Classification of Tumors Editorial Board. Female genital tumors. In: World Health Organization. Classification of tumors. 5th ed (vol. 4). World Health Organization, IARC Press; 5th ed (vol. 4). 2020.

2. World Health Organization. Human papillomavirus (HPV) and cervical cancer: fact sheet. Aug 2023 [internet publication].Texto completo

3. European Commission: European Cancer Information System​. Cervical cancer burden in EU-27. 2021 [internet publication].Texto completo

4. National Cancer Institute: Surveillance, Epidemiology, and End Results (SEER) Program. Cancer stat facts: cervical cancer. 2024 [internet publication].Texto completo

5. Louie KS, de Sanjose S, Diaz M, et al. Early age at first sexual intercourse and early pregnancy are risk factors for cervical cancer in developing countries. Br J Cancer. 2009 Apr 7;100(7):1191-7.Texto completo  Resumo

6. International Collaboration of Epidemiological Studies of Cervical Cancer. Cervical carcinoma and sexual behavior: collaborative reanalysis of individual data on 15,461 women with cervical carcinoma and 29,164 women without cervical carcinoma from 21 epidemiological studies. Cancer Epidemiol Biomarkers Prev. 2009 Apr;18(4):1060-9.Texto completo  Resumo

7. International Collaboration of Epidemiological Studies of Cervical Cancer; Appleby P, Beral V, Berrington de González A, et al. Carcinoma of the cervix and tobacco smoking: collaborative reanalysis of individual data on 13,541 women with carcinoma of the cervix and 23,017 women without carcinoma of the cervix from 23 epidemiological studies. Int J Cancer. 2006 Mar 15;118(6):1481-95.Texto completo  Resumo

8. Liu G, Sharma M, Tan N, et al. HIV-positive women have higher risk of human papilloma virus infection, precancerous lesions, and cervical cancer. AIDS. 2018 Mar 27;32(6):795-808.Texto completo  Resumo

9. Hessol NA, Whittemore H, Vittinghoff E, et al. Incidence of first and second primary cancers diagnosed among people with HIV, 1985-2013: a population-based, registry linkage study. Lancet HIV. 2018 Nov;5(11):e647-55. Resumo

10. Grulich AE, van Leeuwen MT, Falster MO, et al. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet. 2007 Jul 7;370(9581):59-67. Resumo

11. Parikh S, Brennan P, Boffetta P. Meta-analysis of social inequality and the risk of cervical cancer. Int J Cancer. 2003 Jul 10;105(5):687-91.Texto completo  Resumo

12. González CA, Travier N, Luján-Barroso L, et al. Dietary factors and in situ and invasive cervical cancer risk in the European prospective investigation into cancer and nutrition study. Int J Cancer. 2011 Jul 19;129(2):449-59.Texto completo  Resumo

13. International Collaboration of Epidemiological Studies of Cervical Cancer., Appleby P, Beral V, et al. Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. Lancet. 2007 Nov 10;370(9599):1609-21. Resumo

14. Landy R, Pesola F, Castañón A, et al. Impact of cervical screening on cervical cancer mortality: estimation using stage-specific results from a nested case-control study. Br J Cancer. 2016 Oct 25;115(9):1140-6.Texto completo  Resumo

15. Vesco KK, Whitlock EP, Eder M, et al. Screening for cervical cancer: a systematic evidence review for the U.S. Preventive Services Task Force. Rockville, MD: Agency for Healthcare Research and Quality (US); 2011 May.Texto completo  Resumo

16. Lei J, Ploner A, Elfström KM, et al. HPV vaccination and the risk of invasive cervical cancer. N Engl J Med. 2020 Oct 1;383(14):1340-48.Texto completo  Resumo

17. Kjaer SK, Dehlendorff C, Belmonte F, et al. Real-world effectiveness of human papillomavirus vaccination against cervical cancer. J Natl Cancer Inst. 2021 Oct 1;113(10):1329-35.Texto completo  Resumo

18. Guo F, Cofie LE, Berenson AB. Cervical cancer incidence in young U.S. females after human papillomavirus vaccine introduction. Am J Prev Med. 2018 Aug;55(2):197-204.Texto completo  Resumo

19. Falcaro M, Castañon A, Ndlela B, et al. The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study. Lancet. 2021 Dec 4;398(10316):2084-92. Resumo

20. Liao CI, Francoeur AA, Kapp DS, et al. Trends in human papillomavirus-associated cancers, demographic characteristics, and vaccinations in the US, 2001-2017. JAMA Netw Open. 2022 Mar 1;5(3):e222530.Texto completo  Resumo

21. Rahangdale L, Mungo C, O'Connor S, et al. Human papillomavirus vaccination and cervical cancer risk. BMJ. 2022 Dec 15;379:e070115.Texto completo  Resumo

22. Bonjour M, Charvat H, Franco EL, et al. Global estimates of expected and preventable cervical cancers among girls born between 2005 and 2014: a birth cohort analysis. Lancet Public Health. 2021 Jul;6(7):e510-21.Texto completo  Resumo

23. Sharma K, Machalek DA, Toh ZQ, et al. No woman left behind: achieving cervical cancer elimination among women living with HIV. Lancet HIV. 2023 Jun;10(6):e412-20. Resumo

24. World Health Organization. Global strategy to accelerate the elimination of cervical cancer as a public health problem. November 2020 [internet publication].Texto completo

25. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999 Sep;189(1):12-9. Resumo

26. Muñoz N, Bosch FX, de Sanjosé S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003 Feb 6;348(6):518-27.Texto completo  Resumo

27. Castellsague X, Diaz M, de Sanjose S, et al. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst. 2006 Mar 1;98(5):303-15. Resumo

28. Ho GY, Bierman R, Beardsley L, et al. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med. 1998 Feb 12;338(7):423-8.Texto completo  Resumo

29. Franco EL, Villa LL, Sobrinho JP, et al. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis. 1999 Nov;180(5):1415-23.Texto completo  Resumo

30. Centers for Disease Control and Prevention. Manual for the surveillance of vaccine-preventable diseases. Chapter 5: Human papillomavirus. Mar 2022 [internet publication].Texto completo

31. Mayrand MH, Duarte-Franco E, Rodrigues I, et al; Canadian Cervical Cancer Screening Trial Study Group. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med. 2007 Oct 18;357(16):1579-88.Texto completo  Resumo

32. Watson RA. Human papillomavirus: confronting the epidemic – a urologist's perspective. Rev Urol. 2005 Summer;7(3):135-44.Texto completo  Resumo

33. Schwarz E, Freese UK, Gissmann L, et al. Structure and transcription of human papillomavirus sequences in cervical carcinoma cells. Nature. 1985 Mar 7-13;314(6006):111-4. Resumo

34. Yim EK, Park JS. The role of HPV E6 and E7 oncoproteins in HPV-associated cervical carcinogenesis. Cancer Res Treat. 2005 Dec;37(6):319-24.Texto completo  Resumo

35. Ferenczy A, Franco E. Persistent human papillomavirus infection and cervical neoplasia. Lancet Oncol. 2002 Jan;3(1):11-6. Resumo

36. Kelly H, Weiss HA, Benavente Y, et al. Association of antiretroviral therapy with high-risk human papillomavirus, cervical intraepithelial neoplasia, and invasive cervical cancer in women living with HIV: a systematic review and meta-analysis. Lancet HIV. 2018 Jan;5(1):e45-58.Texto completo  Resumo

37. Castellsagué X, Muñoz N. Chapter 3: Cofactors in human papillomavirus carcinogenesis: role of parity, oral contraceptives, and tobacco smoking. J Natl Cancer Inst Monogr. 2003;(31):20-8. Resumo

38. International Collaboration of Epidemiological Studies of Cervical Cancer. Comparison of risk factors for invasive squamous cell carcinoma and adenocarcinoma of the cervix: collaborative reanalysis of individual data on 8,097 women with squamous cell carcinoma and 1,374 women with adenocarcinoma from 12 epidemiological studies. Int J Cancer. 2007 Feb 15;120(4):885-91. Resumo

39. Bowden SJ, Doulgeraki T, Bouras E, et al. Risk factors for human papillomavirus infection, cervical intraepithelial neoplasia and cervical cancer: an umbrella review and follow-up Mendelian randomisation studies. BMC Med. 2023 Jul 27;21(1):274. Resumo

40. Hamar B, Teutsch B, Hoffmann E, et al. Trichomonas vaginalis infection is associated with increased risk of cervical carcinogenesis: a systematic review and meta-analysis of 470 000 patients. Int J Gynaecol Obstet. 2023 Oct;163(1):31-43.Texto completo  Resumo

41. Bhuvanendran Pillai A, Mun Wong C, Dalila Inche Zainal Abidin N, et al. Chlamydia infection as a risk factor for cervical cancer: a systematic review and meta-analysis. Iran J Public Health. 2022 Mar;51(3):508-17.Texto completo  Resumo

42. Iversen L, Sivasubramaniam S, Lee AJ, et al. Lifetime cancer risk and combined oral contraceptives: the Royal College of General Practitioners' oral contraception study. Am J Obstet Gynecol. 2017 Jun;216(6):580.e1-9.Texto completo  Resumo

43. International Collaboration of Epidemiological Studies of Cervical Cancer. Cervical carcinoma and reproductive factors: collaborative reanalysis of individual data on 16,563 women with cervical carcinoma and 33,542 women without cervical carcinoma from 25 epidemiological studies. Int J Cancer. 2006 Sep 1;119(5):1108-24.Texto completo  Resumo

44. Castellsagué X, Bosch FX, Muñoz N, et al. Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners. N Engl J Med. 2002 Apr 11;346(15):1105-12.Texto completo  Resumo

45. Svare EI, Kjaer SK, Worm AM, et al. Risk factors for genital HPV DNA in men resemble those found in women: a study of male attendees at a Danish STD clinic. Sex Transm Infect. 2002 Jun;78(3):215-8.Texto completo  Resumo

46. Kim J, Kim BK, Lee CH, et al. Human papillomavirus genotypes and cofactors causing cervical intraepithelial neoplasia and cervical cancer in Korean women. Int J Gynecol Cancer. 2012 Nov;22(9):1570-6. Resumo

47. Potischman N, Brinton LA. Nutrition and cervical neoplasia. Cancer Causes Control. 1996 Jan;7(1):113-26. Resumo

48. Xu L, Tan Y, Xiang P, et al. Diet-related risk factors for cervical cancer: data from National Health and Nutrition Examination Survey 1999-2018. Nutr Cancer. 2023;75(10):1892-9. Resumo

49. Yeo AS, Schiff MA, Montoya G, et al. Serum micronutrients and cervical dysplasia in Southwestern American Indian women. Nutr Cancer. 2000;38(2):141-50. Resumo

50. Cao D, Shen K, Li Z, et al. Association between vitamin C Intake and the risk of cervical neoplasia: a meta-analysis. Nutr Cancer. 2016;68(1):48-57. Resumo

51. Hu X, Li S, Zhou L, et al. Effect of vitamin E supplementation on uterine cervical neoplasm: a meta-analysis of case-control studies. PLoS One. 2017 Aug 22;12(8):e0183395.Texto completo  Resumo

52. Sikström B, Hellberg D, Nilsson S, et al. Smoking, alcohol, sexual behaviour and drug use in women with cervical human papillomavirus infection. Arch Gynecol Obstet. 1995;256(3):131-7. Resumo

53. Joura EA, Giuliano AR, Iversen OE, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015 Feb 19;372(8):711-23.Texto completo  Resumo

54. Centers for Disease Control and Prevention. Supplemental information and guidance for vaccination providers regarding use of 9-valent HPV vaccine. Nov 2016 [internet publication].Texto completo

55. Munoz N, Manalastas R Jr, Pitisuttithum P, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet. 2009 Jun 6;373(9679):1949-57. Resumo

56. Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med. 2002 Nov 21;347(21):1645-51. Resumo

57. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet. 2004 Nov 13-19;364(9447):1757-65. Resumo

58. Arbyn M, Xu L, Simoens C, et al. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database Syst Rev. 2018 May 9;(5):CD009069.Texto completo  Resumo

59. Brisson M, Kim JJ, Canfell K, et al. Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries. Lancet. 2020 Feb 22;395(10224):575-90.Texto completo  Resumo

60. Marth C, Landoni F, Mahner S, et al. Cervical cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017 Jul 1;28(suppl 4):iv72-83.Texto completo  Resumo

61. Braaten KP, Laufer MR. Human papillomavirus (HPV), HPV-related disease, and the HPV vaccine. Rev Obstet Gynecol. 2008 Winter;1(1):2-10.Texto completo  Resumo

62. Restrepo J, Herrera T, Samakoses R, et al. Ten-year follow-up of 9-valent human papillomavirus vaccine: immunogenicity, effectiveness, and safety. Pediatrics. 2023 Oct 1;152(4):e2022060993.Texto completo  Resumo

63. Kreimer AR, Sampson JN, Porras C, et al. Evaluation of durability of a single dose of the bivalent HPV vaccine: the CVT trial. J Natl Cancer Inst. 2020 Oct 1;112(10):1038-46.Texto completo  Resumo

64. Basu P, Malvi SG, Joshi S, et al. Vaccine efficacy against persistent human papillomavirus (HPV) 16/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort study. Lancet Oncol. 2021 Nov;22(11):1518-29.Texto completo  Resumo

65. Barnabas RV, Brown ER, Onono MA, et al. Efficacy of single-dose HPV vaccination among young African women. NEJM Evid. 2022 Jun;1(5):EVIDoa2100056.Texto completo  Resumo

66. World Health Organization. Human papillomavirus vaccines: WHO position paper, December 2022 [internet publication].Texto completo

67. UK Health Security Agency. Human papillomavirus (HPV): the green book, chapter 18a. Jun 2023 [internet publication].Texto completo

68. UK Health Security Agency. HPV vaccination guidance for healthcare practitioners (version 6). Jun 2023 [internet publication].Texto completo

69. Saslow D, Andrews KS, Manassaram-Baptiste D, et al. Human papillomavirus vaccination 2020 guideline update: American Cancer Society guideline adaptation. CA Cancer J Clin. 2020 Jul;70(4):274-80.Texto completo  Resumo

70. Centers for Disease Control and Prevention. Child and adolescent immunization schedule by age. Nov 2024 [internet publication].Texto completo

71. National Institutes of Health, Centers for Disease Control and Prevention, HIV Medicine Association, and Infectious Diseases Society of America. Panel on Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV. 2024 [internet publication].Texto completo

72. American College of Obstetricians and Gynecologists' Committee on Adolescent Health Care, American College of Obstetricians and Gynecologists' Immunization, Infectious Disease, and Public Health Preparedness Expert Work Group. Human papillomavirus vaccination: ACOG committee opinion, number 809. Obstet Gynecol. 2020 Aug;136(2):e15-21.Texto completo  Resumo

73. Centers for Disease Control and Prevention. Adult immunization schedule by age. Nov 2024 [internet publication].Texto completo

74. Parazzini F, Negri E, La Vecchia C, et al. Barrier methods of contraception and the risk of cervical neoplasia. Contraception. 1989 Nov;40(5):519-30. Resumo

75. Erbelding EJ, Zenilman JM. Toward better control of sexually transmitted diseases. N Engl J Med. 2005 Feb 17;352(7):720-1. Resumo

76. Bulkmans NW, Berkhof J, Rozendaal L, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet. 2007 Nov 24;370(9601):1764-72. Resumo

77. Cortessis VK, Barrett M, Brown Wade N, et al. Intrauterine device use and cervical cancer risk: a systematic review and meta-analysis. Obstet Gynecol. 2017 Dec;130(6):1226-36. Resumo

78. Spotnitz ME, Natarajan K, Ryan PB, et al. Relative risk of cervical neoplasms among copper and levonorgestrel-releasing intrauterine system users. Obstet Gynecol. 2020 Feb;135(2):319-27.Texto completo  Resumo

79. Minalt N, Caldwell A, Yedlicka GM, et al. Association between intrauterine device use and endometrial, cervical, and ovarian cancer: an expert review. Am J Obstet Gynecol. 2023 Aug;229(2):93-100. Resumo

80. Siebers AG, Klinkhamer PJ, Grefte JM, et al. Comparison of liquid-based cytology with conventional cytology for detection of cervical cancer precursors: a randomized controlled trial. JAMA. 2009 Oct 28;302(16):1757-64.Texto completo  Resumo

81. Fontham ETH, Wolf AMD, Church TR, et al. Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society CA Cancer J Clin. 2020 Sep;70(5):321-46.Texto completo  Resumo

82. American College of Obstetricians and Gynecologists. Updated cervical cancer screening guidelines. April 2021 [internet publication].Texto completo

83. Koliopoulos G, Nyaga VN, Santesso N, et al. Cytology versus HPV testing for cervical cancer screening in the general population. Cochrane Database Syst Rev. 2017 Aug 10;(8):CD008587.Texto completo  Resumo

84. Ogilvie GS, van Niekerk D, Krajden M, et al. Effect of screening with primary cervical HPV testing vs cytology testing on high-grade cervical intraepithelial neoplasia at 48 months: the HPV FOCAL randomized clinical trial. JAMA. 2018 Jul 3;320(1):43-52.Texto completo  Resumo

85. Melnikow J, Henderson JT, Burda BU, et al. Screening for cervical cancer with high-risk human papillomavirus testing: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2018 Aug 21;320(7):687-705.Texto completo  Resumo

86. Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda system: terminology for reporting results of cervical cytology. JAMA. 2002 Apr 24;287(16):2114-9. Resumo

87. Nayar R, Wilbur DC. The Pap test and Bethesda 2014. Cancer Cytopathol. 2015 May;123(5):271-81.Texto completo  Resumo

88. Wang J, Andrae B, Sundström K, et al. Risk of invasive cervical cancer after atypical glandular cells in cervical screening: nationwide cohort study. BMJ. 2016 Feb 11;352:i276.Texto completo  Resumo

89. National Cancer Institute Workshop. The 1988 Bethesda System for reporting cervical/vaginal cytological diagnoses. JAMA. 1989 Aug 18;262(7):931-4. Resumo

90. Perkins RB, Guido RS, Castle PE, et al. 2019 ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis. 2020 Apr;24(2):102-31.Texto completo  Resumo

91. American College of Obstetricians and Gynecologists. Updated guidelines for management of cervical cancer screening abnormalities​. October 2020 [internet publication].Texto completo

92. Bhatla N, Aoki D, Sharma DN, et al. Cancer of the cervix uteri: 2021 update. Int J Gynaecol Obstet. 2021 Oct;155 Suppl 1(suppl 1):28-44.Texto completo  Resumo

93. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: cervical cancer [internet publication].Texto completo

94. Patel-Lippmann K, Robbins JB, Barroilhet L, et al. MR imaging of cervical cancer. Magn Reson Imaging Clin N Am. 2017 Aug;25(3):635-49. Resumo

95. Fischerova D, Cibula D, Stenhova H, et al. Transrectal ultrasound and magnetic resonance imaging in staging of early cervical cancer. Int J Gynecol Cancer. 2008 Jul-Aug;18(4):766-72. Resumo

96. Benedet JL, Bender H, Jones H 3rd, et al. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. Int J Gynaecol Obstet. 2000 Aug;70(2):209-62. Resumo

97. Choi HJ, Ju W, Myung SK, et al. Diagnostic performance of computer tomography, magnetic resonance imaging, and positron emission tomography or positron emission tomography/computer tomography for detection of metastatic lymph nodes in patients with cervical cancer: meta-analysis. Cancer Sci. 2010 Jun;101(6):1471-9.Texto completo  Resumo

98. Unger JB, Ivy JJ, Connor P, et al. Detection of recurrent cervical cancer by whole-body FDG PET scan in asymptomatic and symptomatic women. Gynecol Oncol. 2004 Jul;94(1):212-6. Resumo

99. Loft A, Berthelsen AK, Roed H, et al. The diagnostic value of PET/CT scanning in patients with cervical cancer: a prospective study. Gynecol Oncol. 2007 Jul;106(1):29-34. Resumo

100. Gee MS, Atri M, Bandos AI, et al. Identification of distant metastatic disease in uterine cervical and endometrial cancers with FDG PET/CT: analysis from the ACRIN 6671/GOG 0233 multicenter trial. Radiology. 2018 Apr;287(1):176-84.Texto completo  Resumo

101. Schmidt D, Bergeron C, Denton KJ, et al. p16/ki-67 dual-stain cytology in the triage of ASCUS and LSIL Papanicolaou cytology: results from the European equivocal or mildly abnormal Papanicolaou cytology study. Cancer Cytopathol. 2011 Jun 25;119(3):158-66.Texto completo  Resumo

102. US Food and Drug Administration. Recently approved devices: Ventana Medical Systems CINtec PLUS Cytology - P190024. 16 Apr 2020 [internet publication]. Texto completo

103. Bhatla N, Berek JS, Cuello Fredes M, et al. Revised FIGO staging for carcinoma of the cervix uteri. Int J Gynaecol Obstet. 2019 Apr;145(1):129-35. Resumo

104. Corrigendum to "Revised FIGO staging for carcinoma of the cervix uteri" [Int J Gynecol Obstet 145(2019) 129-135]. 2019 Nov;147(2):279-80.Texto completo  Resumo

105. Union for International Cancer Control Classification. UICC and the TNM classification of malignant tumours. June 2021 [internet publication].Texto completo

106. US Preventive Services Task Force. Cervical cancer: screening. Dec 2024 [internet publication].Texto completo

107. NHS England. Cervical screening: programme overview. Jul 2024 [internet publication].Texto completo

108. NHS England. Cervical screening care pathway​. Sep 2024 [internet publication].Texto completo

109. WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention [Internet]. 2nd ed. Geneva: World Health Organization; 2021.Texto completo  Resumo

110. World Health Organization. WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention, second edition: use of mRNA tests for human papillomavirus (‎HPV)‎. Dec 2021 [internet publication].Texto completo

111. Biggar RJ, Chaturvedi AK, Goedert JJ, et al. AIDS-related cancer and severity of immunosuppression in persons with AIDS. J Natl Cancer Inst. 2007 Jun 20;99(12):962-72. Resumo

112. Kyrgiou M, Athanasiou A, Paraskevaidi M, et al. Adverse obstetric outcomes after local treatment for cervical preinvasive and early invasive disease according to cone depth: systematic review and meta-analysis. BMJ. 2016 Jul 28;354:i3633.Texto completo  Resumo

113. Bentivegna E, Gouy S, Maulard A, et al. Oncological outcomes after fertility-sparing surgery for cervical cancer: a systematic review. Lancet Oncol. 2016 Jun;17(6):e240-53. Resumo

114. Reynolds AC, McKenzie LJ. Cancer treatment-related ovarian dysfunction in women of childbearing potential: management and fertility preservation options. J Clin Oncol. 2023 Apr 20;4(12):2281-92.Texto completo  Resumo

115. Alonso-Espías M, Gorostidi M, Gracia M, et al. Role of adjuvant radiotherapy in patients with cervical cancer uUndergoing radical hysterectomy. J Pers Med. 2023 Oct 12;13(10):1486.Texto completo  Resumo

116. Rodriguez J, Viveros-Carreño D, Pareja R. Adjuvant treatment after radical surgery for cervical cancer with intermediate risk factors: is it time for an update? Int J Gynecol Cancer. 2022 Oct 3;32(10):1219-26. Resumo

117. Querleu D, Morrow CP. Classification of radical hysterectomy. Lancet Oncol. 2008 Mar;9(3):297-303. Resumo

118. Querleu D, Cibula D, Abu-Rustum NR. 2017 Update on the Querleu-Morrow classification of radical hysterectomy. Ann Surg Oncol. 2017 Oct;24(11):3406-12.Texto completo  Resumo

119. Schmeler KM, Pareja R, Lopez Blanco A, et al. ConCerv: a prospective trial of conservative surgery for low-risk early-stage cervical cancer. Int J Gynecol Cancer. 2021 Oct;31(10):1317-25.Texto completo  Resumo

120. Kietpeerakool C, Aue-Aungkul A, Galaal K, et al. Nerve-sparing radical hysterectomy compared to standard radical hysterectomy for women with early stage cervical cancer (stage Ia2 to IIa). Cochrane Database Syst Rev. 2019 Feb 12;(2):CD012828.Texto completo  Resumo

121. Plante M, Kwon JS, Ferguson S, et al. Simple versus radical hysterectomy in women with low-risk cervical cancer. N Engl J Med. 2024 Feb 29;390(9):819-29.Texto completo  Resumo

122. Ramirez PT, Frumovitz M, Pareja R, et al. Minimally invasive versus abdominal radical hysterectomy for cervical cancer. N Engl J Med. 2018 Oct 31;379(20):1895-904. Resumo

123. Uppal S, Gehrig PA, Peng K, et al. Recurrence rates in patients with cervical cancer treated with abdominal versus minimally invasive radical hysterectomy: a multi-institutional retrospective review study. J Clin Oncol. 2020 Apr 1;38(10):1030-40. Resumo

124. Melamed A, Margul DJ, Chen L, et al. Survival after minimally invasive radical hysterectomy for early-stage cervical cancer. N Engl J Med. 2018 Oct 31;379(20):1905-14. Resumo

125. Falconer H, Palsdottir K, Stalberg K, et al. Robot-assisted approach to cervical cancer (RACC): an international multi-center, open-label randomized controlled trial. Int J Gynecol Cancer. 2019 Jul;29(6):1072-6. Resumo

126. ClinicalTrials.gov. A trial of robotic versus open hysterectomy surgery in cervix cancer (ROCC). April 2023 [internet publication].Texto completo

127. Committee on Gynecologic Practice. Committee opinion no. 619: gynecologic surgery in the obese woman. Obstet Gynecol. 2015 Jan;125(1):274-8.Texto completo  Resumo

128. Bohn JA, Hernandez-Zepeda ML, Hersh AR, et al. Does obesity influence the preferred treatment approach for early-stage cervical cancer? A cost-effectiveness analysis. Int J Gynecol Cancer. 2022 Feb;32(2):133-40. Resumo

129. Salvo G, Ramirez PT, Leitao MM, et al. Open vs minimally invasive radical trachelectomy in early-stage cervical cancer: International Radical Trachelectomy Assessment Study. Am J Obstet Gynecol. 2022 Jan;226(1):97.e1-97.e16.Texto completo  Resumo

130. Gien LT, Covens A. Fertility-sparing options for early stage cervical cancer. Gynecol Oncol. 2010 May;117(2):350-7. Resumo

131. Slama J, Runnebaum IB, Scambia G, et al. Analysis of risk factors for recurrence in cervical cancer patients after fertility-sparing treatment: the FERTIlity Sparing Surgery retrospective multicenter study. Am J Obstet Gynecol. 2023 Apr;228(4):443.e1-443.e10. Resumo

132. Lintner B, Saso S, Tarnai L, et al. Use of abdominal radical trachelectomy to treat cervical cancer greater than 2 cm in diameter. Int J Gynecol Cancer. 2013 Jul;23(6):1065-70. Resumo

133. Wethington SL, Sonoda Y, Park KJ, et al. Expanding the indications for radical trachelectomy: a report on 29 patients with stage IB1 tumors measuring 2 to 4 centimeters. Int J Gynecol Cancer. 2013 Jul;23(6):1092-8.Texto completo  Resumo

134. Li J, Wu X, Li X, et al. Abdominal radical trachelectomy: Is it safe for IB1 cervical cancer with tumors ≥ 2 cm? Gynecol Oncol. 2013 Oct;131(1):87-92. Resumo

135. Pareja R, Rendón GJ, Sanz-Lomana CM, et al. Surgical, oncological, and obstetrical outcomes after abdominal radical trachelectomy - a systematic literature review. Gynecol Oncol. 2013 Oct;131(1):77-82. Resumo

136. Bentivegna E, Maulard A, Pautier P, et al. Fertility results and pregnancy outcomes after conservative treatment of cervical cancer: a systematic review of the literature. Fertil Steril. 2016 Oct;106(5):1195-211;e5.Texto completo  Resumo

137. Kuznicki ML, Chambers LM, Morton M, et al. Fertility-sparing surgery for early-stage cervical cancer: a systematic review of the literature. J Minim Invasive Gynecol. 2021 Mar;28(3):513-26.e1. Resumo

138. Nezhat C, Roman RA, Rambhatla A, et al. Reproductive and oncologic outcomes after fertility-sparing surgery for early stage cervical cancer: a systematic review. Fertil Steril. 2020 Apr;113(4):685-703.Texto completo  Resumo

139. Chino J, Annunziata CM, Beriwal S, et al. Radiation therapy for cervical cancer: executive summary of an ASTRO clinical practice guideline. Pract Radiat Oncol. 2020 Jul-Aug;10(4):220-34.Texto completo  Resumo

140. Landoni F, Colombo A, Milani R, et al. Randomized study between radical surgery and radiotherapy for the treatment of stage IB-IIA cervical cancer: 20-year update. J Gynecol Oncol. 2017 May;28(3):e34.Texto completo  Resumo

141. Lanciano RM, Won M, Coia LR, et al. Pretreatment and treatment factors associated with improved outcome in squamous cell carcinoma of the uterine cervix: a final report of the 1973 and 1978 patterns of care studies. Int J Radiat Oncol Biol Phys. 1991 Apr;20(4):667-76. Resumo

142. Hanks GE, Herring DF, Kramer S. Patterns of care outcome studies: results of the national practice in cancer of the cervix. Cancer. 1983 Mar 1;51(5):959-67.Texto completo  Resumo

143. Coia L, Won M, Lanciano R, et al. The patterns of care outcome study for cancer of the uterine cervix: results of the second national practice survey. Cancer. 1990 Dec 15;66(12):2451-6. Resumo

144. Montana GS, Martz KL, Hanks GE. Patterns and sites of failure in cervix cancer treated in the U.S.A. in 1978. Int J Radiat Oncol Biol Phys. 1991 Jan;20(1):87-93. Resumo

145. Pötter R, Tanderup K, Schmid MP, et al. MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study. Lancet Oncol. 2021 Apr;22(4):538-47. Resumo

146. Sturdza AE, Knoth J. Image-guided brachytherapy in cervical cancer including fractionation. Int J Gynecol Cancer. 2022 Mar;32(3):273-80.Texto completo  Resumo

147. Schmid MP, Lindegaard JC, Mahantshetty U, et al. Risk factors for local failure following chemoradiation and magnetic resonance image-guided brachytherapy in locally advanced cervical cancer: results from the EMBRACE-I study. J Clin Oncol. 2023 Apr 1;41(10):1933-42. Resumo

148. Green JA, Kirwan JM, Tierney JF, et al. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet. 2001 Sep 8;358(9284):781-6. Resumo

149. Green J, Kirwan J, Tierney J, et al. Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix. Cochrane Database Syst Rev. 2005 Jul 20;(3):CD002225.Texto completo  Resumo

150. Rose PG, Ali S, Watkins E, et al. Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007 Jul 1;25(19):2804-10.Texto completo  Resumo

151. Eifel PJ, Winter K, Morris M, et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01. J Clin Oncol. 2004 Mar 1;22(5):872-80.Texto completo  Resumo

152. Dueñas-González A, Zarbá JJ, Patel F, et al. Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix. J Clin Oncol. 2011 May 1;29(13):1678-85.Texto completo  Resumo

153. Whitney CW, Sause W, Bundy BN, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol. 1999 May;17(5):1339-48. Resumo

154. Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 1999 Apr 15;340(15):1144-53.Texto completo  Resumo

155. Gold MA, Tian C, Whitney CW, et al. Surgical versus radiographic determination of para-aortic lymph node metastases before chemoradiation for locally advanced cervical carcinoma: a Gynecologic Oncology Group Study. Cancer. 2008 May 1;112(9):1954-63.Texto completo  Resumo

156. Cormier B, Diaz JP, Shih K, et al. Establishing a sentinel lymph node mapping algorithm for the treatment of early cervical cancer. Gynecol Oncol. 2011 Aug;122(2):275-80.Texto completo  Resumo

157. Lécuru F, Mathevet P, Querleu D, et al. Bilateral negative sentinel nodes accurately predict absence of lymph node metastasis in early cervical cancer: results of the SENTICOL study. J Clin Oncol. 2011 May 1;29(13):1686-91.Texto completo  Resumo

158. Cibula D, Kocian R, Plaikner A, et al. Sentinel lymph node mapping and intraoperative assessment in a prospective, international, multicentre, observational trial of patients with cervical cancer: The SENTIX trial. Eur J Cancer. 2020 Sep;137:69-80.Texto completo  Resumo

159. Mauro J, Viveros-Carreño D, Vizzielli G, et al. Survival after sentinel node biopsy alone in early-stage cervical cancer: a systematic review. Int J Gynecol Cancer. 2023 Sep 4;33(9):1370-5. Resumo

160. Peters WA 3rd, Liu PY, Barrett RJ 2nd, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol. 2000 Apr;18(8):1606-13. Resumo

161. Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med. 1999 Apr 15;340(15):1137-43.Texto completo  Resumo

162. Keys HM, Bundy BN, Stehman FB, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med. 1999 Apr 15;340(15):1154-61.Texto completo  Resumo

163. Kokka F, Bryant A, Brockbank E, et al. Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer. Cochrane Database Syst Rev. 2015 Apr 7;(4):CD010260.Texto completo  Resumo

164. Monk BJ, Sill MW, McMeekin DS, et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2009 Oct 1;27(28):4649-55.Texto completo  Resumo

165. Kitagawa R, Katsumata N, Shibata T, et al. Paclitaxel plus carboplatin versus paclitaxel plus cisplatin in metastatic or recurrent cervical cancer: the open-label randomized phase III trial JCOG0505. J Clin Oncol. 2015 Jul 1;33(19):2129-35.Texto completo  Resumo

166. Long HJ 3rd, Bundy BN, Grendys EC Jr, et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol. 2005 Jul 20;23(21):4626-33.Texto completo  Resumo

167. Tewari KS, Sill MW, Penson RT, et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet. 2017 Oct 7;390(10103):1654-63.Texto completo  Resumo

168. Rosen VM, Guerra I, McCormack M, et al. Systematic review and network meta-analysis of bevacizumab plus first-line topotecan-paclitaxel or cisplatin-paclitaxel versus non-bevacizumab-containing therapies in persistent, recurrent, or metastatic cervical cancer. Int J Gynecol Cancer. 2017 Jul;27(6):1237-46.Texto completo  Resumo

169. Colombo N, Dubot C, Lorusso D, et al. Pembrolizumab for persistent, recurrent, or metastatic cervical cancer. N Engl J Med. 2021 Nov 11;385(20):1856-67.Texto completo  Resumo

170. Monk BJ, Tewari KS, Dubot C, et al. Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2023 Apr;24(4):392-402.Texto completo  Resumo

171. Chuang LT, Temin S, Berek JS, et al. Management and care of patients with invasive cervical cancer: ASCO resource-stratified guideline rapid recommendation update. JCO Glob Oncol. 2022 Mar;8:e2200027.Texto completo  Resumo

172. Tewari KS, Colombo N, Monk BJ, et al. Pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer: subgroup analyses from the KEYNOTE-826 randomized clinical trial. JAMA Oncol. 2024 Feb 1;10(2):185-92.Texto completo  Resumo

173. Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2020 Jan 1;38(1):1-10.Texto completo  Resumo

174. Vergote I, González-Martín A, Fujiwara K, et al. Tisotumab vedotin as second- or third-line therapy for recurrent cervical cancer. N Engl J Med. 2024 Jul 4;391(1):44-55.Texto completo  Resumo

175. Trifiletti DM, Swisher-McClure S, Showalter TN, et al. Postoperative chemoradiation therapy in high-risk cervical cancer: re-evaluating the findings of Gynecologic Oncology Group Study 109 in a large, population-based cohort. Int J Radiat Oncol Biol Phys. 2015 Dec 1;93(5):1032-44. Resumo

176. Sedlis A, Bundy BN, Rotman MZ, et al. A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: a Gynecologic Oncology Group study. Gynecol Oncol. 1999 May;73(2):177-83. Resumo

177. Kim H, Park W, Kim YS, et al. Chemoradiotherapy is not superior to radiotherapy alone after radical surgery for cervical cancer patients with intermediate-risk factor. J Gynecol Oncol. 2020 May;31(3):e35.Texto completo  Resumo

178. ClinicalTrials.gov (US). Radiation therapy with or without chemotherapy in patients with stage I-IIA cervical cancer who previously underwent surgery (ClinicalTrials.gov Identifier: NCT01101451). May 2022 [internet publication]​.Texto completo

179. Höckel M, Dornhöfer N. Pelvic exenteration for gynaecological tumours: achievements and unanswered questions. Lancet Oncol. 2006 Oct;7(10):837-47. Resumo

180. Peccatori FA, Azim HA Jr, Orecchia R, et al. Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013 Oct;24(suppl 6):vi160-70.Texto completo  Resumo

181. Amant F, Berveiller P, Boere IA, et al. Gynecologic cancers in pregnancy: guidelines based on a third international consensus meeting. Ann Oncol. 2019 Oct 1;30(10):1601-12.Texto completo  Resumo

182. Zagouri F, Sergentanis TN, Chrysikos D, et al. Platinum derivatives during pregnancy in cervical cancer: a systematic review and meta-analysis. Obstet Gynecol. 2013 Feb;121(2 Pt 1):337-43. Resumo

183. European Society for Medical Oncology. eUpdate - cervical cancer treatment recommendations. Apr 2020 [internet publication].Texto completo

184. Cibula D, Kocian R, Plaikner A, et al. Sentinel lymph node mapping and intraoperative assessment in a prospective, international, multicentre, observational trial of patients with cervical cancer: the SENTIX trial. Eur J Cancer. 2020 Sep;137:69-80.Texto completo  Resumo

185. McCormack M, Gallardo Rincón D, Eminowicz G​. A randomised phase III trial of induction chemotherapy followed by chemoradiation compared with chemoradiation alone in locally advanced cervical cancer: the GCIG INTERLACE trial. Ann Oncol. 2023;34(suppl)2S1-2:S1276​.Texto completo

186. McCormack M, Eminowicz G, Gallardo D, et al. Induction chemotherapy followed by standard chemoradiotherapy versus standard chemoradiotherapy alone in patients with locally advanced cervical cancer (GCIG INTERLACE): an international, multicentre, randomised phase 3 trial. Lancet. 2024 Oct 19;404(10462):1525-35.Texto completo  Resumo

187. Janku F, Wheler JJ, Westin SN, et al. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol. 2012 Mar 10;30(8):777-82.Texto completo  Resumo

188. Juric D, Rodon J, Tabernero J, et al. Phosphatidylinositol 3-kinase α-selective inhibition with alpelisib (BYL719) in PIK3CA-altered solid tumors: results from the first-in-human study. J Clin Oncol. 2018 May 1;36(13):1291-9.Texto completo  Resumo

189. Wallecha A, French C, Petit R, et al. Lm-LLO-based immunotherapies and HPV-associated disease. J Oncol. 2012;2012:542851.Texto completo  Resumo

190. Basu P, Mehta AO, Jain MM, et al. ADXS11-001 immunotherapy targeting HPV-E7: final results from a phase 2 study in Indian women with recurrent cervical cancer. J Clin Oncol. 2014;32:5(suppl);5610.

191. Huh WK, Dizon DS, Powell MA, et al. ADXS11-001 immunotherapy in squamous or non-squamous persistent/recurrent metastatic cervical cancer: results from stage I of the phase II GOG/NRG0265 study. J Clin Oncol. 2016;34:S5516.Texto completo

192. Basu P, Mehta A, Jain M, et al. A randomized phase 2 study of ADXS11-001 Listeria monocytogenes-listeriolysin O immunotherapy with or without cisplatin in treatment of advanced cervical cancer. Int J Gynecol Cancer. 2018 May;28(4):764-72.Texto completo  Resumo

193. Keam SJ. Cadonilimab: First Approval. Drugs. 2022 Aug;82(12):1333-39. Resumo

194. Wu X, Sun Y, Yang H, et al. Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China. Lancet. 2024 Oct 26;404(10463):1668-76. Resumo

195. Trimble CL, Morrow MP, Kraynyak KA, et al. Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial. Lancet. 2015 Nov 21;386(10008):2078-88.Texto completo  Resumo

196. Bhuyan PK, Dallas M, Kraynyak K, et al. Durability of response to VGX-3100 treatment of HPV16/18 positive cervical HSIL. Hum Vaccin Immunother. 2021 May 4;17(5):1288-93.Texto completo  Resumo

197. Stevanović S, Draper LM, Langhan MM, et al. Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. J Clin Oncol. 2015 May 10;33(14):1543-50.Texto completo  Resumo

198. Rydzewska L, Tierney J, Vale CL, et al. Neoadjuvant chemotherapy plus surgery versus surgery for cervical cancer. Cochrane Database Syst Rev. 2012 Dec 12;(12):CD007406.Texto completo  Resumo

199. Zou W, Han Y, Zhang Y, et al. Neoadjuvant chemotherapy plus surgery versus concurrent chemoradiotherapy in stage IB2-IIB cervical cancer: a systematic review and meta-analysis. PLoS One. 2019;14(11):e0225264.Texto completo  Resumo

200. Marchetti C, Fagotti A, Tombolini V, et al. Survival and toxicity in neoadjuvant chemotherapy plus surgery versus definitive chemoradiotherapy for cervical cancer: a systematic review and meta-analysis. Cancer Treat Rev. 2020 Feb;83:101945. Resumo

201. Friedlander M, Grogan M; US Preventive Services Task Force. Guidelines for the treatment of recurrent and metastatic cervical cancer. Oncologist. 2002;7(4):342-7.Texto completo  Resumo

202. Elit L, Fyles AW, Oliver TK, et al. Follow-up for women after treatment for cervical cancer. Curr Oncol. 2010 Jun;17(3):65-9.Texto completo  Resumo

203. Suk R, Mahale P, Sonawane K, et al. Trends in risks for second primary cancers associated with index human papillomavirus-associated cancers. JAMA Netw Open. 2018 Sep 7;1(5):e181999.Texto completo  Resumo

204. Aue-Aungkul A, Kietpeerakool C, Rattanakanokchai S, et al. Postoperative interventions for preventing bladder dysfunction after radical hysterectomy in women with early-stage cervical cancer. Cochrane Database Syst Rev. 2021 Jan 25;(1):CD012863.Texto completo  Resumo

205. Qian M, Wang L, Xing J, et al. Prevalence of sexual dysfunction in women with cervical cancer: a systematic review and meta-analysis. Psychol Health Med. 2023 Feb;28(2):494-508. Resumo

206. Shan X, Qian M, Wang L, et al. Prevalence of pelvic floor dysfunction and sexual dysfunction in cervical cancer survivors: a systematic review and meta-analysis. Int Urogynecol J. 2023 Mar;34(3):655-64. Resumo

207. Cianci S, Tarascio M, Arcieri M, et al. Post treatment sexual function and quality of life of patients affected by cervical cancer: a systematic review. Medicina (Kaunas). 2023 Apr 4;59(4):704.Texto completo  Resumo

208. Kirchheiner K, Nout RA, Lindegaard JC, et al. Dose-effect relationship and risk factors for vaginal stenosis after definitive radio(chemo)therapy with image-guided brachytherapy for locally advanced cervical cancer in the EMBRACE study. Radiother Oncol. 2016 Jan;118(1):160-6. Resumo

209. Penson RT, Wenzel LB, Vergote I, et al. Quality of life considerations in gynecologic cancer: FIGO 6th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet. 2006 Nov;95(suppl 1):S247-57. Resumo

210. Fokdal L, Pötter R, Kirchheiner K, et al. Physician assessed and patient reported urinary morbidity after radio-chemotherapy and image guided adaptive brachytherapy for locally advanced cervical cancer. Radiother Oncol. 2018 Jun;127(3):423-30. Resumo

211. Jensen NBK, Pötter R, Kirchheiner K, et al. Bowel morbidity following radiochemotherapy and image-guided adaptive brachytherapy for cervical cancer: Physician- and patient reported outcome from the EMBRACE study. Radiother Oncol. 2018 Jun;127(3):431-9. Resumo

212. Zhou X, Yao Z, Bai H, et al. Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis. Lancet Oncol. 2021 Sep;22(9):1265-74. Resumo

213. Naqash AR, Moey MYY, Cherie Tan XW, et al. Major adverse cardiac events with immune checkpoint inhibitors: a pooled analysis of trials sponsored by the National Cancer Institute-Cancer Therapy Evaluation Program. J Clin Oncol. 2022 Oct 10;40(29):3439-52.Texto completo  Resumo

214. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: management of immunotherapy-related toxicities​ [internet publication].Texto completo

215. Schneider BJ, Naidoo J, Santomasso BD, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021 Dec 20;39(36):4073-126.Texto completo  Resumo

216. Haanen J, Obeid M, Spain L, et al. Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022 Dec;33(12):1217-38.Texto completo  Resumo

217. Laenens D, Yu Y, Santens B, et al. Incidence of cardiovascular events in patients treated with immune checkpoint inhibitors. J Clin Oncol. 2022 Oct 10;40(29):3430-8.Texto completo  Resumo

218. Cibula D, Raspollini MR, Planchamp F, et al. ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer - Update 2023. Int J Gynecol Cancer. 2023 May 1;33(5):649-66.Texto completo  Resumo

219. Salani R, Khanna N, Frimer M, et al. An update on post-treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncology (SGO) recommendations. Gynecol Oncol. 2017 Jul;146(1):3-10. Resumo

O uso deste conteúdo está sujeito ao nosso aviso legal